Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: Success, disappointment, and new opportunities

M.D. Blunt, S.G. Ward

Research output: Contribution to journalArticle

14 Citations (Scopus)
105 Downloads (Pure)

Abstract

The predominant expression of the γ and δ isoforms of PI3K in cells of hematopoietic lineage prompted speculation that inhibitors of these isoforms could offer opportunities for selective targeting of PI3K in the immune system in a range of immune-related pathologies. While there has been some success in developing PI3Kδ inhibitors, progress in developing selective inhibitors of PI3Kγ has been rather disappointing. This has prompted the search for alternative targets with which to modulate PI3K signaling specifically in the immune system. One such target is the SH2 domain-containing inositol-5-phosphatase1 (SHIP-1) which de-phosphorylates PI(3,4,5)P at the D5 position of the inositol ring to create PI(3,4)P. In this article, we first describe the current state of PI3K isoformselective inhibitor development. We then focus on the structure of SHIP-1 and its function in the immune system. Finally, we consider the current state of development of small molecule compounds that potently and selectively modulate SHIP activity and which offer novel opportunities to manipulate PI3K mediated signaling in the immune system.
Original languageEnglish
Article number226
JournalFrontiers in Immunology
Volume3
Early online date1 Aug 2012
DOIs
Publication statusPublished - 2 Aug 2012

Fingerprint Dive into the research topics of 'Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: Success, disappointment, and new opportunities'. Together they form a unique fingerprint.

  • Cite this